The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | Real-world insights into the use of belantamab mafodotin-based comboinations in R/R MM
Elena Zamagni, MD, PhD, University of Bologna, Bologna, Italy, discusses the real-world use of belantamab mafodotin-based combinations in relapsed/refractory multiple myeloma (R/R MM), noting that physicians select combinations with bortezomib and pomalidomide equally often. Dr Zamagni highlights that the bortezomib combination is being used in daratumumab-refractory patients, and also shows promise as an option for elderly and frail patients. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
